Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jon A Erickson

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Journal of Neurochemistry|December 9, 2004
Biochemical and kinetic characterization of BACE1: investigation into the putative species-specificity for beta- and beta'-cleavage sites by human and murine BACE1Hsiu-Chiung Yang, Xiyun Chai, Marian Mosior, et al.
Bioorganic & Medicinal Chemistry|May 24, 2015
Preparation and biological evaluation of conformationally constrained BACE1 inhibitorsLeonard L Winneroski, Matthew A Schiffler, Jon A Erickson, et al.
Bioorganic & Medicinal Chemistry|December 2, 2019
Preparation and biological evaluation of BACE1 inhibitors: Leveraging trans-cyclopropyl moieties as ligand efficient conformational constraintsLeonard L Winneroski, Jon A Erickson, Steven J Green, et al.
Journal of Medicinal Chemistry|June 3, 2021
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE InhibitorDavid L McKinzie, Leonard L Winneroski, Steven J Green, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|January 23, 2015
The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humansPatrick C May, Brian A Willis, Stephen L Lowe, et al.
Journal of Medicinal Chemistry|December 23, 2016
Discovery of (1S,2R,3S,4S,5R,6R)-2-Amino-3-[(3,4-difluorophenyl)sulfanylmethyl]-4-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid Hydrochloride (LY3020371·HCl): A Potent, Metabotropic Glutamate 2/3 Receptor Antagonist with Antidepressant-Like ActivityMark D Chappell, Renhua Li, Stephon C Smith, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Journal of Neurochemistry|December 9, 2004
Biochemical and kinetic characterization of BACE1: investigation into the putative species-specificity for beta- and beta'-cleavage sites by human and murine BACE1Hsiu-Chiung Yang, Xiyun Chai, Marian Mosior, et al.
Bioorganic & Medicinal Chemistry|May 24, 2015
Preparation and biological evaluation of conformationally constrained BACE1 inhibitorsLeonard L Winneroski, Matthew A Schiffler, Jon A Erickson, et al.
Bioorganic & Medicinal Chemistry|December 2, 2019
Preparation and biological evaluation of BACE1 inhibitors: Leveraging trans-cyclopropyl moieties as ligand efficient conformational constraintsLeonard L Winneroski, Jon A Erickson, Steven J Green, et al.
Journal of Medicinal Chemistry|June 3, 2021
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE InhibitorDavid L McKinzie, Leonard L Winneroski, Steven J Green, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|January 23, 2015
The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humansPatrick C May, Brian A Willis, Stephen L Lowe, et al.
Journal of Medicinal Chemistry|December 23, 2016
Discovery of (1S,2R,3S,4S,5R,6R)-2-Amino-3-[(3,4-difluorophenyl)sulfanylmethyl]-4-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid Hydrochloride (LY3020371·HCl): A Potent, Metabotropic Glutamate 2/3 Receptor Antagonist with Antidepressant-Like ActivityMark D Chappell, Renhua Li, Stephon C Smith, et al.
Pageof 2